Brief Summary
The main purpose of the master is to help the research sites and sponsor carry out several clinical trialsresearch studies performed to test new treatments, tests or procedures and evaluate their effectiveness on various diseases more efficiently by providing a common research protocol. Individual clinical trials under this master protocol define drug/disease-specific research goals and activities to test them. New studies will be added as new drugs emerge against different cancers. Participation in the trial will depend on how long the benefit lasts.
Intervention / Treatment
- Drug: Ramucirumab
- Drug: Cyclophosphamide
- Drug: Vinorelbine
- Drug: Gemcitabine
- Drug: Docetaxel
- Drug: Abemaciclib
- Drug: Irinotecan
- Drug: Temozolomide
Inclusion Criteria:
Participants must meet all of the inclusion criteria below. Additional criteria are specified in the protocol amendment (individual addenda) to which the participant will enroll.
- Have either measurable or evaluable disease using standard techniques by the Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1).
- The participant has a Lansky (<16 years of age) or Karnofsky (≥16 years of age) performance score of at least 50.
- Participants must have discontinued all previous treatments for cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs or investigational agents greater than or equal to (≥)7 days after the last dosethe amount of medication taken and must have recovered from clinically significant side effects.
- The participant has adequate hematologic and organ function.
- Female participants of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to first dose.
- Both female and male participants of childbearing potential must agree to use highly effective contraceptive precautions during the trial and for at least 3 months following the last dose of study drug.